16:24 , Mar 17, 2017 |  BC Week In Review  |  Company News

Aptuit, BioVersys deal

Aptuit partnered with BioVersys to discover and validate targets in Gram-negative bacteria. Aptuit will provide in vitro and in vivo discovery services. BioVersys will contribute an undisclosed target to the collaboration. BioVersys declined to provide...
00:00 , Mar 17, 2017 |  BC Extra  |  Clinical News

Small molecule can bypass tuberculosis drug resistance

A team led by researchers at the University of Lille identified a small molecule that can circumvent tuberculosis resistance to the prodrug ethionamide and reinstate sensitivity to the compound. Ethionamide's activation is catalyzed by the...
07:00 , Jun 9, 2014 |  BC Week In Review  |  Company News

BioVersys AG, GlaxoSmithKline, Wellcome Trust deal

BioVersys and GlaxoSmithKline partnered to develop a preclinical compound and two backup compounds to treat tuberculosis (TB). BioVersys has been developing the compounds, which are designed to improve the efficacy of existing TB drug ethionamide,...
08:00 , Feb 10, 2014 |  BC Week In Review  |  Company News

BioVersys, SARomics Biostructures deal

BioVersys and SARomics partnered to discover small molecules that block the transcriptional activation of undisclosed resistance genes to restore the efficacy and antibiotic activity of undisclosed marketed drugs. The companies said they will combine their...
07:00 , Oct 10, 2013 |  BC Innovations  |  Translation in Brief

Translational tidbits

Focusing the BRAIN The NIH 's BRAIN initiative has developed a road map for its near-term research priorities, chief among which is conducting a census of brain cells. Whether the ambitious, decades-long project will be...
07:00 , Sep 23, 2013 |  BC Week In Review  |  Company News

BioVersys, University of Applied Science North Western Switzerland, University of Basel, University of Berne, University of Geneva, Zurich University of Applied

BioVersys said Switzerland's Commission for Technology and Innovation (CTI) will support a consortium comprising BioVersys and the universities with an overall budget of CHF2.1 million ($2.3 million) to develop compounds to combat antibiotic resistances. BioVersys...
07:00 , Jul 1, 2013 |  BC Week In Review  |  Financial News

BioVersys completes venture financing

BioVersys AG , Basel, Switzerland   Business: Infectious   Date completed: 6/27/13   Type: Venture financing   Raised: Not disclosed   Investors: Existing investors; new investors   Note: The company closed an oversubscribed, undisclosed series...
01:24 , Jun 29, 2013 |  BC Extra  |  Financial News

BioVersys closes series A

BioVersys AG (Basel, Switzerland) closed an oversubscribed series A round with an undisclosed amount from new and existing investors. BioVersys is developing compounds that restore antibiotic sensitivity by targeting regulatory pathways that mediate drug resistance....